GlassScriptPhysician profile
Jessica Petty
NPI 1447631627
$5,312.54
in general payments reported to CMS, 2019-2025
22 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $12.02 · 2021: $12.09 · 2022: $254 · 2023: $4,165 · 2024: $398 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,057 · Food and Beverage: $1,259 · Travel and Lodging: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,057.48 |
| Food and Beverage | $1,258.73 |
| Travel and Lodging | $536.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,775.02 | 2022-2024 | Da Vinci Surgical System, Da Vinci Sp |
| Glaxosmithkline, LLC. | $265.27 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Inspire Medical Systems, INC. | $260.47 | 2023-2025 | Inspire |
| Baxter Healthcare | $139.23 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.28 | 2019-2023 | Tezspire, Fasenra |
| Grifols USA, LLC | $93.17 | 2023-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $76.53 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.76 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.07 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Amgen INC. | $37.34 | 2022 | |
| Mylan Specialty L.P. | $29.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.03 | 2024 | Dupixent |
| Philips North America LLC | $25.53 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.73 | 2023 | Gvoke Hypopen |
| Zoll Respicardia, INC. | $23.84 | 2025 | Remede System |
| Abbvie INC. | $23.66 | 2022 | |
| Viiv Healthcare Company | $22.96 | 2024 | Cabenuva |
| Edwards Lifesciences Corporation | $22.89 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $18.92 | 2024 | Arcalyst |
| Organon LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.